New Service: In Vitro Assay for Fibrosis Evaluation
We are delighted to announce the launch of our new in vitro assay service for fibrosis evaluation.
By launching this service, we now offer a cost-effective and efficient way to conduct preliminary studies and screen compounds for potential fibrotic effects, saving valuable time and resources in your drug development journey. This not only speeds up the early stages of your drug discovery process but also mitigates the risk associated with investing in full-scale animal studies prematurely.
e.g. The anti-fibrotic effect of compounds in human fetal lung fibroblast cells (HEL299 cells)
Summary of Study:
The HEL299 cells are maintained in EMEM with 10% FBS. 10 ng/mL recombinant human TGF-β is added to the medium to stimulate cells. After stimulation by TGF-β, the cells are treated with test compounds for 24 h. The cells were subsequently harvested and measured for fibrosis related factor (e.g. α-SMA) mRNA levels using qPCR.
Over the years, we have been conducted in providing premier drug efficacy evaluation study services, focusing on inflammation, fibrosis and oncology as a non-clinical CRO. We have been able to accelerate the drug development pipeline through this service and contribute to advancing many of the compounds for which no cure is yet available into clinical trials.
Should you have any questions or if you wish to discuss how this new service can benefit your current and future projects, please feel free to contact us.